5 assets in Dihydropyrimidine Dehydrogenase Deficiency

Therapeutic assets addressing Dihydropyrimidine Dehydrogenase Deficiency, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Nivolumab Dihydropyrimidine Dehydrogenase Deficiency	UNICANCER	P2	CCC (53)
Panitumumab Dihydropyrimidine Dehydrogenase Deficiency	UNICANCER	P2	CCC (53)
Trastuzumab Dihydropyrimidine Dehydrogenase Deficiency	UNICANCER	P2	CCC (53)
Trifluridine Dihydropyrimidine Dehydrogenase Deficiency	UNICANCER	P2	CCC (53)
Oxaliplatin Dihydropyrimidine Dehydrogenase Deficiency	UNICANCER	P2	CCC (51)